Grant: Discovery Grants Program - Individual
McGill University
$33,000.00
Genetic Engineering of Mammalian Sensory Circuits
EF 2015-16
Résumé
Optogenetics has emerged as a powerful tool to control neuronal activity with high spatio-temporal precision. We were the first to develop optogenetic strategies to activate selectively genetically-defined peripheral somatosensory neurons involved in nociception and pain in mice (Daou et al., 2013). In this 5-year research program, we propose to design and validate conditional transgenic models for the functional interrogation of neuronal subsets with unclear roles in somatosensory circuits.<span style=""line-height: 1.5em;"">Our main scientific objectives are:
<span style=""line-height: 1.5em;""><span style=""line-height: 1.5em;"">1) To interrogate genetically-identified neurons in somatosensory circuits in vivo using optogenetics. <span style=""line-height: 1.5em;"">Primary sensory neurons are located in the dorsal root, trigeminal, and nodose ganglia while their peripheral terminals and fibers innervate the skin and peripheral tissues. Their activation is directly linked to somatosensory modalities (touch, temperature, itch, nociception) and to pain perception. We previously used the ""proof-of-concept"" Nav1.8-Cre driver with broad neuronal expression but we propose now to interrogate more specific subsets of genetically-defined neurons: thermal peptidergic nociceptors with TRPV1-Cre, tactile non-peptidergic nociceptors with MrgD-Cre, itch sensors with MrgA3-Cre and mechanosensors with TH-Cre. Once their optical activation with ChR2 or inhibition with Arch is demonstrated in vitro and in vivo behaviorally in normal conditions (tactile response, thermal sensitivity, conditioned place aversion), we will test their contribution to chronic pain following inflammation or neuropathic injury using behavioral analysis and quantitative sensory measurements.
2) To modulate selectively the two main types of nociceptors in vivo using chemogenetics. Peripheral sensitization of nociceptors plays a major role in triggering central mechanisms of chronic pain. We have shown that TRPC3-linked Gq-coupled pathways contribute to peripheral sensitization in nociceptors (Alkhani et al., 2014). Using AAV viral expression of two chemogenetic actuators, the DREADDs M3D (Gq-coupled) and M4D (Gi-coupled) activated by the compound CNO, we propose to investigate the functional consequences of CNO-induced modulation of TRPV1+ and MrgD+ nociceptor firing in transgenic mice in vitro and in vivo. We make the hypothesis that activation of M3D Gq-coupled pathways will promote sensitization and inflammation, while M4D Gi-coupled pathways will protect DRG/TG neurons from sensitization and hyperexcitability, recruiting cellular mechanisms analogous to morphine analgesia.
These novel transgenic mice engineered with artificial peripheral transducers/receptors will allow us to dissect in vitro the signaling diversity of sensory neurons as well as to investigate in vivo the contribution of specific neuronal populations to several modalities of somatosensation relevant to pain, in normal and sensitized states.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2015-04876
Name nom
Séguéla, Philippe
Department département
Neurology and Neurosurgery - Neurology and Neurosurgery
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
33000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Partie
1
Nb partie
5
Application title
Genetic Engineering of Mammalian Sensory Circuits
Keyword
NSERC
Application summary
<p>Optogenetics has emerged as a powerful tool to control neuronal activity with high spatio-temporal precision. We were the first to develop optogenetic strategies to activate selectively genetically-defined peripheral somatosensory neurons involved in nociception and pain in mice (Daou et al., 2013). In this 5-year research program, we propose to design and validate conditional transgenic models for the functional interrogation of neuronal subsets with unclear roles in somatosensory circuits.<span style=""line-height: 1.5em;"">Our main scientific objectives are:</span></p>
<p><span style=""line-height: 1.5em;""></span><span style=""line-height: 1.5em;""><strong>1) To interrogate genetically-identified neurons in somatosensory circuits in vivo using optogenetics.</strong> </span><span style=""line-height: 1.5em;"">Primary sensory neurons are located in the dorsal root, trigeminal, and nodose ganglia while their peripheral terminals and fibers innervate the skin and peripheral tissues. Their activation is directly linked to somatosensory modalities (touch, temperature, itch, nociception) and to pain perception. We previously used the ""proof-of-concept"" Nav1.8-Cre driver with broad neuronal expression but we propose now to interrogate more specific subsets of genetically-defined neurons: thermal peptidergic nociceptors with TRPV1-Cre, tactile non-peptidergic nociceptors with MrgD-Cre, itch sensors with MrgA3-Cre and mechanosensors with TH-Cre. Once their optical activation with ChR2 or inhibition with Arch is demonstrated in vitro and in vivo behaviorally in normal conditions (tactile response, thermal sensitivity, conditioned place aversion), we will test their contribution to chronic pain following inflammation or neuropathic injury using behavioral analysis and quantitative sensory measurements.</span></p>
<p><strong>2) To modulate selectively the two main types of nociceptors in vivo using chemogenetics.</strong> Peripheral sensitization of nociceptors plays a major role in triggering central mechanisms of chronic pain. We have shown that TRPC3-linked Gq-coupled pathways contribute to peripheral sensitization in nociceptors (Alkhani et al., 2014). Using AAV viral expression of two chemogenetic actuators, the DREADDs M3D (Gq-coupled) and M4D (Gi-coupled) activated by the compound CNO, we propose to investigate the functional consequences of CNO-induced modulation of TRPV1+ and MrgD+ nociceptor firing in transgenic mice in vitro and in vivo. We make the hypothesis that activation of M3D Gq-coupled pathways will promote sensitization and inflammation, while M4D Gi-coupled pathways will protect DRG/TG neurons from sensitization and hyperexcitability, recruiting cellular mechanisms analogous to morphine analgesia. <br />
These novel transgenic mice engineered with artificial peripheral transducers/receptors will allow us to dissect in vitro the signaling diversity of sensory neurons as well as to investigate in vivo the contribution of specific neuronal populations to several modalities of somatosensation relevant to pain, in normal and sensitized states.</p>